Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Details

Language :

English

ISSN :

0732183X

Volume :

26

Issue :

4

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

105862180